Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Ingelheim buys Pharmaxis NASH candidate

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim is to pay €27.5m up front plus upwards of €500m in milestones to acquire a Phase I candidate that has shown preclinical promise in non-alcoholic steatohepatitis (NASH) from Pharmaxis. The German company is exercising an option that it already held to acquire the investigational drug PXS4728A, a semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor that is designed to block leucocyte adhesion and tissue infiltration in inflammatory processes.

You may also be interested in...



Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV

With a Phase II AOC3 inhibitor and a pair of preclinical partnerships with RNAi companies, the German pharma is taking its time to investigate a variety of approaches to the multi-factorial disease.

Find Resources To Designate IVDR Notified Bodies, Commission Tells Member States

There is growing impetus at the highest EU levels towards ensuring the IVD Regulation is implemented as quickly and effectively as possible. Discussion at the Council of the EU have now added to this drive.

NPA Alleges US FDA Bends Time As Well As Rules To Stop NAC’s Use As Dietary Ingredient

Trade group offers timeline for shift in FDA thinking about the amino acid commonly used in supplements in complaint seeking to block agency from preventing sales of NAC-containing supplements. Complaint also attests that, unlike its current stance, FDA in 1993 acknowledged NAC is lawful for use as a dietary ingredient.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel